CASPS is a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial. 48 participants were randomly assigned (2:1) to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Participants were unblinded at week 24 or sooner if they had progression; those on placebo crossed over to cediranib and all participants continued on treatment until progression or death.

Clinical data and sample collection.